Stay updated on TACTI-002: IMP321 Combo Study NSCLC HNSCC Clinical Trial

Sign up to get notified when there's something new on the TACTI-002: IMP321 Combo Study NSCLC HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TACTI-002: IMP321 Combo Study NSCLC HNSCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.3%
    Check dated 2024-06-13T21:10:13.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in medical or healthcare-related publications or documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:29:26.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating an update in the number of versions of the study record for the clinical trial NCT03625323. This change likely reflects a new submission or modification in the documentation related to the study on the combination therapy with Eftilagimod Alpha and Pembrolizumab for certain types of cancer.
    Difference
    0.3%
    Check dated 2024-05-22T20:59:16.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:17:45.000Z thumbnail image

Stay in the know with updates to TACTI-002: IMP321 Combo Study NSCLC HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TACTI-002: IMP321 Combo Study NSCLC HNSCC Clinical Trial page.